Alzheimer's and Dementia: Translational Research and Clinical Interventions
ESCI-ISI SCOPUS (SonsInc.)
2352-8737
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)
Phân tích ảnh hưởng
Các bài báo tiêu biểu
Inflammation as a central mechanism in Alzheimer's diseaseAbstract Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by cognitive decline and the presence of two core pathologies, amyloid β plaques and neurofibrillary tangles. Over the last decade, the presence of a sustained immune response in the brain has emerged as a third core pathology in AD. The sustained activation of the br... ...
Tập 4 Số 1 - Trang 575-590 - 2018
Alzheimer's disease drug development pipeline: 2018Abstract Introduction Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III.Results There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on hiện toàn bộ
Tập 4 Số 1 - Trang 195-214 - 2018
Alzheimer's disease drug development pipeline: 2017Abstract Introduction There is an urgent need to develop new treatments for Alzheimer's disease (AD) and to understand the drug development process for new AD therapies. Methods We assessed the agents in the AD pipeline as documented in hiện toàn bộ
Tập 3 Số 3 - Trang 367-384 - 2017
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain healthAbstract Cognitive decline leading to dementia represents a global health burden. In the absence of targeted pharmacotherapy, lifestyle approaches remain the best option for slowing the onset of dementia. However, older adults spend very little time doing moderate to vigorous exercise and spend a majority of time in sedentary behavior. Sedentary behavior has been li... ...
Tập 3 Số 3 - Trang 291-300 - 2017
Accelerating drug development for Alzheimer's disease through the use of data standardsAbstract Introduction The exceedingly high rate of failed trials in Alzheimer's disease (AD) calls for immediate attention to improve efficiencies and learning from past, ongoing, and future trials. Accurate, highly rigorous standardized data are at the core of meaningful scientific research. Data standards allow for proper integrat...
Tập 3 - Trang 273-283 - 2017
Amyloid‐associated increases in longitudinal report of subjective cognitive complaintsAbstract Introduction To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. Methods Two hundred seventy‐ni...
Tập 4 - Trang 444-449 - 2018
Institutionalization risk and costs associated with agitation in Alzheimer's diseaseAbstract Introduction Agitation in individuals with Alzheimer's disease (AD) may predict institutionalization. This study assessed the incremental risk and costs associated with agitation in individuals with AD. Methods A retrospective analysis of the National Alzheimer's ...
Tập 5 - Trang 851-861 - 2019
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigmsAbstract Neuropsychiatric symptoms (NPSs) are hallmarks of Alzheimer's disease (AD), causing substantial distress for both people with dementia and their caregivers, and contributing to early institutionalization. They are among the earliest signs and symptoms of neurocognitive disorders and incipient cognitive decline, yet are under‐recognized and often challenging... ...
Tập 3 - Trang 440-449 - 2017
Reconsidering frameworks of Alzheimer's dementia when assessing psychosocial outcomesAbstract The purpose of this introductory article to the special issue on psychosocial outcome measures in Alzheimer's & Dementia: Translational Research & Clinical Interventions is to outline new frameworks to more effectively capture and measure the full range of how people living with Alzheimer's dementia and their family caregi... ...
Tập 5 - Trang 388-397 - 2019
Hearing treatment for reducing cognitive decline: Design and methods of the Aging and Cognitive Health Evaluation in Elders randomized controlled trialAbstract Introduction Hearing impairment is highly prevalent and independently associated with cognitive decline. The Aging and Cognitive Health Evaluation in Elders study is a multicenter randomized controlled trial to determine efficacy of hearing treatment in reducing cognitive decline in older adults. ...
Tập 4 - Trang 499-507 - 2018